Show simple item record

dc.contributor.authorMartin-Blazquez, Ariadna
dc.contributor.authorMartin-Lorenzo, Marta
dc.contributor.authorSantiago-Hernandez, Aranzazu
dc.contributor.authorHeredero, Angeles
dc.contributor.authorDonado, Alicia
dc.contributor.authorLopez, Juan A
dc.contributor.authorAnfaiha-Sanchez, Miriam
dc.contributor.authorRuiz-Jimenez, Rocio
dc.contributor.authorEsteban, Vanesa 
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorAldamiz-Echevarria, Gonzalo
dc.contributor.authorAlvarez-Llamas, Gloria
dc.date.accessioned2024-05-17T10:02:17Z
dc.date.available2024-05-17T10:02:17Z
dc.date.issued2024-04-09
dc.identifier.citationJ Proteome Res. 2024 Apr 9.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19444
dc.description.abstractThoracic aortic aneurysm (TAA) is mainly sporadic and with higher incidence in the presence of a bicuspid aortic valve (BAV) for unknown reasons. The lack of drug therapy to delay TAA progression lies in the limited knowledge of pathophysiology. We aimed to identify the molecular hallmarks that differentiate the aortic dilatation associated with BAV and tricuspid aortic valve (TAV). Aortic vascular smooth muscle cells (VSMCs) isolated from sporadic TAA patients with BAV or TAV were analyzed by mass spectrometry. DNA oxidative damage assay and cell cycle profiling were performed in three independent cohorts supporting proteomics data. The alteration of secreted proteins was confirmed in plasma. Stress phenotype, oxidative stress, and enhanced DNA damage response (increased S-phase arrest and apoptosis) were found in BAV-TAA patients. The increased levels of plasma C1QTNF5, LAMA2, THSB3, and FAP confirm the enhanced stress in BAV-TAA. Plasma FAP and BGN point to an increased inflammatory condition in TAV. The arterial wall of BAV patients shows a limited capacity to counteract drivers of sporadic TAA. The molecular pathways identified support the need of differential molecular diagnosis and therapeutic approaches for BAV and TAV patients, showing specific markers in plasma which may serve to monitor therapy efficacy.es_ES
dc.description.sponsorshipThis study was supported by the Instituto de Salud Carlos III with cofunding from the ERDF (PI20/01103, CP22/00100, FI21/00128, IF08/3667-1, PI21/00158, PRB3[IPT17/0019- ISCIII-SGEFI/ERDF], RD16/0009, RD21/0005/0001), the Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00 and PID2021-122348NB-I00), Getinge Group Spain SL, CAM (PEJ-2020-AI/BMD-17899, PEJD-2019-PRE/BMD-16992, 2018-T2/BMD-11561, PIPF2022/SAL-GL-25760), Fundacioń SENEFRO/SEN, Fundacioń Mutua Madrileña and Fundacioń Conchita Rabago ́ de Jimenez ́ Dí az, and “la Caixa” Banking Foundation (project codes HR17-00247 and HR22-00253). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovacioń (MCIN), and the Pro CNIC Foundation) and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/ AEI/10.13039/501100011033).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Chemical Society (ACS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleAnalysis of Vascular Smooth Muscle Cells from Thoracic Aortic Aneurysms Reveals DNA Damage and Cell Cycle Arrest as Hallmarks in Bicuspid Aortic Valve Patients.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID38594816es_ES
dc.identifier.doi10.1021/acs.jproteome.3c00649es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderFundación Mutua Madrileña es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderFundación Conchita Rábago de Jiménez Díaz es_ES
dc.contributor.funderFundación La Caixa es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1535-3907es_ES
dc.relation.publisherversion10.1021/acs.jproteome.3c00649es_ES
dc.identifier.journalJournal of proteome researches_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI20/01103es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CP22/00100es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FI21/00128es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/IF08/3667-1es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI21/00158es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0009es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD21/0005/0001es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PGC2018-097019-B-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-122348NB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PEJ-2020-AI/BMD-17899es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PEJD-2019-PRE/BMD-16992es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2018-T2/BMD-11561es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PIPF2022/SAL-GL-25760es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/HR17-00247es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/HR22-00253es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MICIN/AEI/10.13039/501100011033/CEX2020-001041-Ses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional